A Phase I Study to Assess the Safety and Pharmacokinetics of huC242-DM4 [monoclonal antibody C242 DM4-conjugate] Administered as a Single Intravenous Infusion Once Every Three Weeks to Subjects With Solid Tumors.
Latest Information Update: 06 Jan 2010
At a glance
- Drugs Cantuzumab ravtansine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ImmunoGen
- 22 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Apr 2008 The expected completion date for this trial is now 1 Feb 2010.